Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.45 |
| ▸ | CTSS | P25774 | 17/20 | 0.44 |
| ▸ | CTSK | P43235 | 16/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 4/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22143680 | 1.00 | CTSL (0.45) | CTSLCTSSCTSKKLK5CTSB | |
| SCHEMBL22143600 | 1.00 | CTSL (0.45) | CTSLCTSSCTSKKLK5CTSB | |
| SCHEMBL25152801 | 0.91 | CTSL (0.45) | CTSLCTSSCTSKKLK5CTSB | |
| SCHEMBL22125812 | 0.90 | CTSS (0.48) | CTSLCTSSCTSKCTSB | |
| SCHEMBL22125814 | 0.90 | CTSS (0.48) | CTSLCTSSCTSKCTSB | |
| SCHEMBL31277258 | 0.85 | MAPT (0.49) | CTSLCTSSCTSKKLK5TACR1 | |
| SCHEMBL18930698 | 0.85 | CTSS (0.44) | CTSLCTSSCTSKKLK5CTSB | |
| SCHEMBL21144829 | 0.85 | CTSS (0.44) | CTSLCTSSCTSKKLK5CTSB | |
| SCHEMBL21144758 | 0.85 | TACR1 (0.46) | CTSLCTSSCTSKKLK5CTSB | |
| SCHEMBL18930474 | 0.85 | TACR1 (0.46) | CTSLCTSSCTSKKLK5CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377425-B1 | Small molecule modulators of IL-17 | LEO PHARMA A/S (DK) | 2022-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377425-B1 | Small molecule modulators of IL-17 | IL17A, IL15, IL2 | CTSL 1110/4885CTSS 757/4885CTSK 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.